Cynapsus Therapeutics Inc. (CTH.V)
-TSXV 0.33 
0.01(3.13%) May 17, 3:33PM EDT
| Prev Close: | 0.32 |
|---|
| Open: | 0.33 |
|---|
| Bid: | 0.32 |
|---|
| Ask: | 0.34 |
|---|
| 1y Target Est: | N/A |
|---|
| Beta: | N/A |
|---|
| Next Earnings Date: | N/A |
|---|
| Day's Range: | 0.33 - 0.33 |
|---|
| 52wk Range: | 0.30 - 0.90 |
|---|
| Volume: | 1,900 |
|---|
| Avg Vol (3m): | 10,925 |
|---|
| Market Cap: | 4.65M |
|---|
| P/E (ttm): | N/A |
|---|
| EPS (ttm): | N/A |
|---|
| Div & Yield: | N/A (N/A) |
|---|
Quotes delayed, except where indicated otherwise. Currency in CAD.
Headlines
- Cynapsus Therapeutics Publishes White Paper on Apomorphine for 'Off' Periods in Parkinson's Disease and Its Alternative Delivery Development Candidate APL-130277Marketwired(Wed, May 15)
- Cynapsus Therapeutics Publishes White Paper on Apomorphine for 'Off' Periods in Parkinson's Disease and Its Alternative Delivery Development Candidate APL-130277Marketwired(Wed, May 15)
- Cynapsus Therapeutics Inc. : Cynapsus Therapeutics Publishes White Paper on Apomorphine for 'Off' Periods in Parkinson's Disease and Its Alternative Delivery Development Candidate APL-130277Thomson Reuters ONE(Wed, May 15)
- Cynapsus Therapeutics Appoints Two New DirectorsMarketwired(Thu, May 9)
- Cynapsus Therapeutics Appoints Two New DirectorsMarketwired(Thu, May 9)
- Cynapsus Announces Completion of Short Form Prospectus OfferingMarketwired(Thu, May 9)
- Cynapsus Grants Stock OptionsMarketwired(Wed, May 1)
- Cynapsus Grants Stock OptionsMarketwired(Wed, May 1)
- Cynapsus Therapeutics Reports 2012 Financial Results and Highlights Key DevelopmentsMarketwired(Fri, Apr 26)
- Cynapsus Therapeutics Reports 2012 Financial Results and Highlights Key DevelopmentsMarketwired(Fri, Apr 26)
- Cynapsus Raises Additional $1.3 Million As Part Of Short Form Prospectus OfferingMarketwired(Thu, Mar 21)
- Cynapsus Announces Continuation of Short Form Prospectus OfferingMarketwired(Thu, Mar 14)
- IIROC Trading Resumption - CTHCNW Group(Mon, Mar 4)
- Cynapsus Therapeutics Completes $6 Million Short Form Prospectus OfferingMarketwired(Mon, Mar 4)
- Cynapsus Therapeutics Completes $6 Million Short Form Prospectus OfferingMarketwired(Fri, Mar 1)
Key Statistics
| Forward P/E (1 yr): | N/A |
|---|
| P/S (ttm): | N/A |
|---|
| Ex-Dividend Date: | N/A |
|---|
Analysts
| Annual EPS Est
()
: | N/A |
|---|
| Quarterly EPS Est
()
: | N/A |
|---|
| Mean Recommendation*: | N/A |
|---|
| PEG Ratio (5 yr expected): | N/A |
|---|
Business Summary
Cynapsus Therapeutics Inc., a specialty pharmaceutical company, engages in developing an improved dosing formulation of an approved drug used to treat the symptoms of Parkinsons disease.
View More